Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Clopidogrel in Hispanic Patients with Stable CAD
NCT01523366Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in coronary artery disease (CAD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Inhibition of the P2Y12 Receptor (P2Y12 Reaction Units). Started Apr 2012; status: completed.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01523366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01523366.